We study the natural history, pathogenesis, prognosis, and treatment of immune mediated kidney diseases. Our studies have focused on the efficacy and toxicity of immunosuppressive treatment regimens for proliferative lupus nephritis, membranous lupus nephropathy, and idiopathic membranous nephropathy. We have completed prospective randomized clinical trials of immunosuppressive drug therapies for proliferative lupus nephritis and membranous lupus nephropathy. A prospective clinical study of combination rituximab and cyclosporine therapy for idiopathic membranous nephropathy is in progress.
To optimize the treatment of immune mediated kidney diseases, additional studies are needed to further define the pathogenesis of these conditions and to develop novel treatment strategies that target the underlying immunologic abnormalities.